Intercept Pharmaceuticals Company Profile (NASDAQ:ICPT)

About Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals logoIntercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ICPT
  • CUSIP: 45845P10
  • Web: interceptpharma.com
Capitalization:
  • Market Cap: $2.61241 billion
  • Outstanding Shares: 25,100,000
Average Prices:
  • 50 Day Moving Avg: $117.73
  • 200 Day Moving Avg: $117.69
  • 52 Week Range: $96.63 - $172.95
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.11
  • P/E Growth: -1.06
Sales & Book Value:
  • Annual Revenue: $70.92 million
  • Price / Sales: 36.84
  • Book Value: $6.76 per share
  • Price / Book: 15.40
Profitability:
  • EBIDTA: ($361,260,000.00)
  • Net Margins: -543.35%
  • Return on Equity: -135.24%
  • Return on Assets: -54.37%
Debt:
  • Debt-to-Equity Ratio: 2.05%
  • Current Ratio: 6.61%
  • Quick Ratio: 6.61%
Misc:
  • Average Volume: 441,602 shs.
  • Beta: -2.01
  • Short Ratio: 13.25
 

Frequently Asked Questions for Intercept Pharmaceuticals (NASDAQ:ICPT)

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) posted its quarterly earnings data on Monday, July, 31st. The company reported ($3.46) earnings per share for the quarter, topping the consensus estimate of ($3.62) by $0.16. The firm had revenue of $30.89 million for the quarter, compared to analysts' expectations of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The company's quarterly revenue was up 459.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($3.14) EPS. View Intercept Pharmaceuticals' Earnings History.

When will Intercept Pharmaceuticals make its next earnings announcement?

Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Intercept Pharmaceuticals.

Where is Intercept Pharmaceuticals' stock going? Where will Intercept Pharmaceuticals' stock price be in 2017?

15 brokerages have issued 12-month price objectives for Intercept Pharmaceuticals' shares. Their predictions range from $69.00 to $350.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $213.31 in the next year. View Analyst Ratings for Intercept Pharmaceuticals.

What are analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:

  • 1. Cantor Fitzgerald analysts commented, "In AESOP, OCA-treated PSC patients demonstrated significant decrease from baseline in alkaline phosphatase (ALP) of -22% compared with placebo-treated patients' increase of +1% at 24 weeks," the firm said."Additionally, CONTROL demonstrated atorvastatin's ability to reduce elevations of LDL-C in OCA-treated patients by 40-48mg/dL." (8/8/2017)
  • 2. According to Zacks Investment Research, "Intercept received a boost with the approval of Ocaliva in 2016 and the initial uptake of the same has been encouraging. The drug’s sale is expected to pick up further in 2017. The PBC market holds strong potential.  We are also encouraged by Intercept’s efforts to develop the drug for additional indications. A potential label expansion of the drug will further boost sales. The company does not expect much contribution from international markets in 2017 and most of it will be loaded in the second half as it works to obtain reimbursements in various European countries. However, expenses are expected to continue to rise as the company invests in commercial activities related to Ocaliva. We also remain concerned about the lack of other late-stage candidates in Intercept’s pipeline.  Moreover, the company’s share underperformed the industry in the last one year." (7/11/2017)
  • 3. Cowen and Company analysts commented, "We hosted a group investor lunch recently with ICPT management." (6/12/2017)
  • 4. BMO Capital Markets analysts commented, "We are raising our PT to $221 from $198 as we believe updated launch metrics suggest continued steady uptake of Ocaliva for PBC driven by greater physician awareness and more open access, supporting our above-consensus 2017 sales estimates. We believe the removal of the REGENERATE enrollment overhang could allow ICPT shares to trade up meaningfully on any signs of efficacy in PSC Ph2 as it remains a source of upside to our and Street estimates. We expect Ocaliva sales growth and development milestones to help ICPT shares recover." (2/24/2017)
  • 5. Wedbush analysts commented, "We believe several clinical catalysts later this year could provide upside to ICPT's current price. Q4/FY:16 Financials: Q4/FY:16 Ocaliva sales were $13.4MM/$18.2MM. Revenues of $13.8MM/$24.9MM also came in higher than consensus estimates of $8.96MM/$20.16MM. GAAP (loss) of $(4.84)/$16.74) came in lower than consensus estimates of $(3.68)/($15.63) on higher than expected SG&A expenses. We have incorporated Q4/FY:16 financials and updated our model based on 2017 guidance. ICPT ended 2016 with cash balance of $689.4MM. Progress on the Ocaliva launch. ICPT appears to be making significant progress with reimbursement, with the time to filled-prescription now at three weeks." (2/24/2017)

Who are some of Intercept Pharmaceuticals' key competitors?

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the folowing people:

  • Paolo Fundaro, Independent Chairman of the Board
  • Mark Pruzanski M.D., President, Chief Executive Officer, Director
  • Sandip S. Kapadia, Chief Financial Officer, Treasurer
  • Lisa Bright, President, International
  • Jerome Benedict Durso, Chief Operating Officer
  • David Ford, Chief Human Resource Officer
  • Richard Kim, Senior Vice President, Commercial U.S.
  • Rachel L. McMinn Ph.D., Chief Business and Strategy Officer
  • David M. Shapiro M.D., Chief Medical Officer
  • Srinivas Akkaraju M.D. Ph.D., Independent Director

Who owns Intercept Pharmaceuticals stock?

Intercept Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Carmignac Gestion (8.11%), Capital World Investors (7.67%), Vanguard Group Inc. (5.31%), State Street Corp (2.99%) and First Trust Advisors LP (1.15%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, Daniel G Welch, David Shapiro, Klaus R Dr Veitinger, Lisa Bright, Mark Pruzanski, Nicole Williams, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Institutional Ownership Trends for Intercept Pharmaceuticals.

Who sold Intercept Pharmaceuticals stock? Who is selling Intercept Pharmaceuticals stock?

Intercept Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Marshall Wace North America L.P., Capital World Investors, State Street Corp, UBS Asset Management Americas Inc., Macquarie Group Ltd., AXA and Schwab Charles Investment Management Inc.. Company insiders that have sold Intercept Pharmaceuticals stock in the last year include Barbara Gayle Duncan, Daniel G Welch, David Shapiro, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Insider Buying and Selling for Intercept Pharmaceuticals.

Who bought Intercept Pharmaceuticals stock? Who is buying Intercept Pharmaceuticals stock?

Intercept Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Vanguard Group Inc., First Trust Advisors LP, Quantitative Investment Management LLC, Asymmetry Capital Management L.P., FMR LLC, Sphera Funds Management LTD. and Northern Trust Corp. View Insider Buying and Selling for Intercept Pharmaceuticals.

How do I buy Intercept Pharmaceuticals stock?

Shares of Intercept Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of Intercept Pharmaceuticals stock can currently be purchased for approximately $104.08.


MarketBeat Community Rating for Intercept Pharmaceuticals (NASDAQ ICPT)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  628 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  896
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $213.31 (104.95% upside)

Analysts' Ratings History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/8/2017Cantor FitzgeraldReiterated RatingUnderweight$60.00 -> $69.00MediumView Rating Details
8/1/2017LaidlawReiterated RatingHold$115.00 -> $119.00HighView Rating Details
8/1/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$200.00LowView Rating Details
8/1/2017BMO Capital MarketsBoost Price TargetOutperform$218.00 -> $221.00MediumView Rating Details
7/31/2017WedbushReiterated RatingBuyHighView Rating Details
7/30/2017Jefferies Group LLCReiterated RatingBuy$275.00HighView Rating Details
6/12/2017Cowen and CompanyReiterated RatingBuyMediumView Rating Details
6/3/2017Credit Suisse GroupSet Price TargetBuy$201.00MediumView Rating Details
2/28/2017Citigroup Inc.Set Price TargetBuy$275.00 -> $240.00N/AView Rating Details
2/24/2017Leerink SwannLower Price TargetMarket Perform$116.00 -> $110.00N/AView Rating Details
2/23/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
2/16/2017Robert W. BairdReiterated RatingOutperform$332.00N/AView Rating Details
2/16/2017FBR & CoReiterated RatingMarket Perform$200.00N/AView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
9/28/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
8/5/2016Morgan StanleyReiterated RatingSell$80.00N/AView Rating Details
6/1/2016Barclays PLCReiterated RatingBuy$200.00 -> $205.00N/AView Rating Details
5/31/2016Goldman Sachs Group, Inc. (The)Boost Price TargetNeutral$114.00 -> $128.00N/AView Rating Details
4/9/2016Bank of America CorporationReiterated RatingSell$144.00N/AView Rating Details
1/28/2016S&P Equity ResearchReiterated RatingAverage$100.60 -> $111.91N/AView Rating Details
(Data available from 8/20/2015 forward)

Earnings

Earnings History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Earnings by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
Earnings History by Quarter for Intercept Pharmaceuticals (NASDAQ ICPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($3.48)N/AView Earnings Details
7/31/2017Q2 2017($3.62)($3.46)$27.50 million$30.89 millionViewN/AView Earnings Details
5/4/2017Q1 2017($4.27)($3.61)$15.88 million$21.00 millionViewListenView Earnings Details
2/23/2017Q416($3.74)($4.84)$8.96 million$13.00 millionViewN/AView Earnings Details
11/3/2016Q316($3.82)($3.59)$4.77 million$4.70 millionViewN/AView Earnings Details
8/4/2016Q216($3.69)($3.14)$1.72 million$5.52 millionViewN/AView Earnings Details
5/5/2016Q1($3.60)($3.33)$0.49 million$0.45 millionViewN/AView Earnings Details
2/23/2016Q415($3.15)($3.62)$0.43 million$0.45 millionViewListenView Earnings Details
11/9/2015Q315($2.74)($2.10)$0.42 million$0.45 millionViewN/AView Earnings Details
8/5/2015Q215($1.95)($1.99)$2.17 million$0.45 millionViewN/AView Earnings Details
5/11/2015Q115($1.75)($1.78)$1.70 million$1.70 millionViewListenView Earnings Details
3/2/2015Q414($1.53)($1.63)$0.42 million$0.04 millionViewN/AView Earnings Details
11/6/2014Q3($1.10)($1.69)$0.46 million$0.45 millionViewN/AView Earnings Details
8/11/2014Q214($1.10)$1.51$400.00 million$405.40 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.72)($1.59)$0.41 million$0.41 millionViewN/AView Earnings Details
3/14/2014Q4 13($0.70)($0.64)ViewN/AView Earnings Details
11/14/2013Q313($0.51)($1.65)$0.89 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.51)($0.79)$0.40 million$0.41 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)
2017 EPS Consensus Estimate: ($14.92)
2018 EPS Consensus Estimate: ($11.29)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($4.62)($3.39)($4.02)
Q2 20175($3.87)($3.28)($3.66)
Q3 20175($3.78)($3.49)($3.61)
Q4 20175($3.95)($3.19)($3.62)
Q1 20181($3.57)($3.57)($3.57)
Q2 20181($3.06)($3.06)($3.06)
Q3 20181($2.57)($2.57)($2.57)
Q4 20181($2.09)($2.09)($2.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Intercept Pharmaceuticals (NASDAQ:ICPT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Insider Ownership Percentage: 9.20%
Institutional Ownership Percentage: 83.05%
Insider Trades by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
Insider Trades by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/2/2017Lisa BrightInsiderSell142$110.29$15,661.18View SEC Filing  
8/1/2017David ShapiroCMOSell1,118$119.00$133,042.00View SEC Filing  
7/31/2017Daniel G WelchDirectorSell602$123.93$74,605.86View SEC Filing  
7/31/2017Rachel McminnInsiderSell130$123.12$16,005.60View SEC Filing  
7/20/2017Daniel G WelchDirectorSell217$126.76$27,506.92View SEC Filing  
7/14/2017Richard J KimSVPSell89$128.64$11,448.96View SEC Filing  
7/11/2017David ShapiroCMOSell553$124.01$68,577.53View SEC Filing  
7/3/2017David ShapiroCMOSell350$121.24$42,434.00View SEC Filing  
7/3/2017Lisa BrightInsiderSell394$121.33$47,804.02View SEC Filing  
7/3/2017Mark PruzanskiCEOSell1,434$121.78$174,632.52View SEC Filing  
7/3/2017Richard J KimSVPSell50$121.69$6,084.50View SEC Filing  
7/3/2017Sandip KapadiaCFOSell1,431$121.59$173,995.29View SEC Filing  
6/26/2017Mark PruzanskiCEOSell40,000$130.80$5,232,000.00View SEC Filing  
6/1/2017Lisa BrightInsiderSell698$110.73$77,289.54View SEC Filing  
5/25/2017Lisa BrightInsiderSell254$117.52$29,850.08View SEC Filing  
5/16/2017Lisa BrightInsiderSell113$119.74$13,530.62View SEC Filing  
5/2/2017Lisa BrightInsiderSell426$114.00$48,564.00View SEC Filing  
5/1/2017David ShapiroCMOSell1,117$112.18$125,305.06View SEC Filing  
5/1/2017Rachel McminnInsiderSell114$113.12$12,895.68View SEC Filing  
4/10/2017David ShapiroCMOSell558$108.51$60,548.58View SEC Filing  
4/3/2017David ShapiroCMOSell346$115.00$39,790.00View SEC Filing  
4/3/2017Lisa BrightInsiderSell389$115.00$44,735.00View SEC Filing  
4/3/2017Mark PruzanskiCEOSell1$115.00$115.00View SEC Filing  
2/27/2017Lisa BrightInsiderSell254$119.48$30,347.92View SEC Filing  
1/31/2017Lisa BrightInsiderSell134$108.96$14,600.64View SEC Filing  
1/9/2017David ShapiroCMOSell1,565$106.01$165,905.65View SEC Filing  
1/3/2017David ShapiroCMOSell988$103.92$102,672.96View SEC Filing  
1/3/2017Mark PruzanskiCEOSell2,802$103.92$291,183.84View SEC Filing  
1/3/2017Rachel McminnInsiderSell816$103.92$84,798.72View SEC Filing  
12/2/2016David ShapiroCMOSell1,350$99.75$134,662.50View SEC Filing  
11/25/2016Lisa BrightInsiderSell249$113.60$28,286.40View SEC Filing  
10/31/2016Rachel McminnInsiderSell129$123.82$15,972.78View SEC Filing  
10/10/2016David ShapiroCMOSell411$153.34$63,022.74View SEC Filing  
10/3/2016Barbara Gayle DuncanCAOSell147$163.20$23,990.40View SEC Filing  
10/3/2016David ShapiroCMOSell1,513$163.08$246,740.04View SEC Filing  
10/3/2016Lisa BrightInsiderSell155$163.20$25,296.00View SEC Filing  
10/3/2016Mark PruzanskiCEOSell705$163.20$115,056.00View SEC Filing  
9/26/2016David ShapiroCMOSell3,545$165.08$585,208.60View SEC Filing  
9/20/2016Mark PruzanskiCEOSell35,000$165.00$5,775,000.00View SEC Filing  
8/25/2016Lisa BrightInsiderSell246$159.00$39,114.00View SEC Filing  
8/1/2016Rachel McminnInsiderSell125$176.57$22,071.25View SEC Filing  
7/5/2016Barbara Gayle DuncanCAOSell146$145.11$21,186.06View SEC Filing  
7/5/2016David ShapiroCMOSell163$145.11$23,652.93View SEC Filing  
7/5/2016Lisa BrightInsiderSell155$145.11$22,492.05View SEC Filing  
7/5/2016Mark PruzanskiCEOSell714$145.11$103,608.54View SEC Filing  
5/25/2016Lisa BrightInsiderSell251$137.50$34,512.50View SEC Filing  
5/2/2016Rachel McminnInsiderSell130$147.49$19,173.70View SEC Filing  
4/4/2016Barbara Gayle DuncanCFOSell144$130.76$18,829.44View SEC Filing  
4/4/2016David ShapiroCMOSell165$130.76$21,575.40View SEC Filing  
4/4/2016Lisa BrightInsiderSell153$130.76$20,006.28View SEC Filing  
4/4/2016Mark PruzanskiCEOSell708$130.76$92,578.08View SEC Filing  
2/25/2016Lisa BrightInsiderSell241$115.22$27,768.02View SEC Filing  
2/1/2016Rachel McminnInsiderSell128$103.56$13,255.68View SEC Filing  
1/13/2016Lisa BrightinsiderSell728$125.52$91,378.56View SEC Filing  
1/4/2016Barbara Gayle DuncanCFOSell468$145.90$68,281.20View SEC Filing  
1/4/2016David ShapiroCMOSell533$145.90$77,764.70View SEC Filing  
1/4/2016Mark PruzanskiCEOSell2,126$145.90$310,183.40View SEC Filing  
1/4/2016Rachel McminnInsiderSell469$145.90$68,427.10View SEC Filing  
11/25/2015Lisa BrightInsiderSell1,150$182.96$210,404.00View SEC Filing  
11/16/2015David ShapiroCMOSell4,264$178.53$761,251.92View SEC Filing  
11/10/2015David ShapiroCMOSell3,500$204.15$714,525.00View SEC Filing  
11/10/2015Klaus R. Dr VeitingerDirectorSell1,000$198.25$198,250.00View SEC Filing  
11/2/2015Rachel McminnInsiderSell125$160.24$20,030.00View SEC Filing  
10/2/2015Barbara Gayle DuncanCFOSell1,054$163.17$171,981.18View SEC Filing  
10/2/2015David ShapiroCMOSell1,140$160.12$182,536.80View SEC Filing  
9/21/2015Nicole WilliamsDirectorSell973$194.82$189,559.86View SEC Filing  
9/15/2015David ShapiroCMOSell3,500$191.28$669,480.00View SEC Filing  
8/17/2015David ShapiroCMOSell4,272$209.37$894,428.64View SEC Filing  
7/20/2015Nicole WilliamsDirectorSell973$279.01$271,476.73View SEC Filing  
7/10/2015Mark PruzanskiCEOSell12,500$250.00$3,125,000.00View SEC Filing  
7/6/2015Luciano AdoriniInsiderSell4,067$579.93$2,358,575.31View SEC Filing  
7/1/2015Barbara Gayle DuncanCFOSell1,000$242.10$242,100.00View SEC Filing  
7/1/2015David ShapiroCMOSell3,781$238.66$902,373.46View SEC Filing  
6/22/2015Nicole WilliamsDirectorSell974$265.14$258,246.36View SEC Filing  
6/15/2015David ShapiroCMOSell3,500$241.58$845,530.00View SEC Filing  
6/8/2015Luciano AdoriniInsiderSell4,000$248.40$993,600.00View SEC Filing  
5/11/2015Klaus R Dr VeitingerDirectorSell391$279.07$109,116.37View SEC Filing  
5/6/2015Luciano AdoriniInsiderSell4,000$259.97$1,039,880.00View SEC Filing  
4/20/2015Nicole WilliamsDirectorSell974$278.50$271,259.00View SEC Filing  
4/6/2015Luciano AdoriniInsiderSell4,000$269.64$1,078,560.00View SEC Filing  
4/2/2015David ShapiroCMOSell3,459$275.25$952,089.75View SEC Filing  
3/26/2015Orbimed Advisors LlcDirectorSell157,200$286.75$45,077,100.00View SEC Filing  
3/25/2015Orbimed Advisors LlcDirectorSell207,800$274.41$57,022,398.00View SEC Filing  
3/24/2015Jonathan SilversteinDirectorSell45,600$272.00$12,403,200.00View SEC Filing  
3/23/2015Jonathan SilversteinDirectorSell159,400$275.18$43,863,692.00View SEC Filing  
3/16/2015David ShapiroCMOSell3,500$286.90$1,004,150.00View SEC Filing  
1/12/2015Klaus R Dr VeitingerDirectorSell233$150.01$34,952.33View SEC Filing  
1/5/2015Barbara Gayle DuncanCFOSell141$176.49$24,885.09View SEC Filing  
1/5/2015Daniel Paul ReganInsiderSell146$176.49$25,767.54View SEC Filing  
1/5/2015David ShapiroCMOSell664$172.63$114,626.32View SEC Filing  
1/5/2015Mark PruzanskiCEOSell461$176.49$81,361.89View SEC Filing  
1/2/2015Barbara Gayle DuncanCFOSell1,000$156.40$156,400.00View SEC Filing  
11/17/2014David ShapiroCMOSell4,790$158.82$760,747.80View SEC Filing  
11/12/2014Srinivas AkkarajuDirectorBuy2,000$167.19$334,380.00View SEC Filing  
11/10/2014Klaus R Dr VeitingerDirectorSell233$175.95$40,996.35View SEC Filing  
11/3/2014Mark PruzanskiCEOSell10,000$259.41$2,594,100.00View SEC Filing  
10/10/2014Klaus R Dr VeitingerDirectorSell391$223.65$87,447.15View SEC Filing  
10/2/2014David ShapiroCMOSell5,020$231.63$1,162,782.60View SEC Filing  
10/1/2014Barbara Gayle DuncanCFOSell1,000$233.12$233,120.00View SEC Filing  
10/1/2014David ShapiroCMOSell4,188$231.17$968,139.96View SEC Filing  
10/1/2014Mark PruzanskiCEOSell10,000$228.82$2,288,200.00View SEC Filing  
9/15/2014David ShapiroCMOSell4,000$281.19$1,124,760.00View SEC Filing  
9/10/2014Klaus R Dr VeitingerDirectorSell391$280.50$109,675.50View SEC Filing  
9/2/2014Mark PruzanskiCEOSell10,000$286.49$2,864,900.00View SEC Filing  
8/27/2014David ShapiroCMOSell10,000$293.93$2,939,300.00View SEC Filing  
8/26/2014Orbimed Advisors LlcDirectorSell111,258$298.06$33,161,559.48View SEC Filing  
8/25/2014Jonathan SilversteinDirectorSell50,000$295.59$14,779,500.00View SEC Filing  
8/15/2014David ShapiroCMOSell4,774$291.49$1,391,573.26View SEC Filing  
8/12/2014Daniel Paul ReganInsiderSell8,124$325.70$2,645,986.80View SEC Filing  
8/12/2014Klaus R Dr VeitingerDirectorSell316$345.62$109,215.92View SEC Filing  
8/1/2014Mark PruzanskiCEOSell10,000$226.72$2,267,200.00View SEC Filing  
7/10/2014Klaus R Dr VeitingerDirectorSell391$219.15$85,687.65View SEC Filing  
7/7/2014Lorenzo TallarigoDirectorSell2,000$243.06$486,120.00View SEC Filing  
7/2/2014David ShapiroCMOSell5,036$244.73$1,232,460.28View SEC Filing  
7/1/2014Mark PruzanskiCEOSell10,000$250.61$2,506,100.00View SEC Filing  
6/16/2014David ShapiroCMOSell4,000$278.15$1,112,600.00View SEC Filing  
6/2/2014Mark PruzanskiCEOSell10,000$230.60$2,306,000.00View SEC Filing  
5/9/2014Lorenzo TallarigoDirectorSell2,007$254.68$511,142.76View SEC Filing  
5/1/2014Mark PruzanskiCEOSell10,000$263.17$2,631,700.00View SEC Filing  
4/16/2014Mark PruzanskiCEOSell10,000$242.22$2,422,200.00View SEC Filing  
4/14/2014Barbara Gayle DuncanCFOSell1,154$279.00$321,966.00View SEC Filing  
4/10/2014Lorenzo TallarigoDirectorSell349,318$317.71$110,981,821.78View SEC Filing  
4/9/2014Orbimed Advisors LlcDirectorSell81,305$320.00$26,017,600.00View SEC Filing  
4/7/2014Luciano AdoriniInsiderSell2,000$283.90$567,800.00View SEC Filing  
4/2/2014David ShapiroCMOSell5,393$331.83$1,789,559.19View SEC Filing  
3/17/2014David ShapiroCMOSell4,456$437.49$1,949,455.44View SEC Filing  
2/14/2014Paolo FundaroDirectorSell7,246$375.26$2,719,133.96View SEC Filing  
1/16/2014Mark PruzanskiCEOSell10,000$273.68$2,736,800.00View SEC Filing  
1/16/2014Srinivas AkkarajuDirectorSell3,250$267.94$870,805.00View SEC Filing  
1/8/2014David ShapiroCMOSell4,928$71.85$354,076.80View SEC Filing  
1/7/2014Lorenzo TallarigoDirectorSell1,839$67.41$123,966.99View SEC Filing  
1/7/2014Luciano AdoriniInsiderSell1,634$67.41$110,147.94View SEC Filing  
12/16/2013David ShapiroCMOSell5,016$62.11$311,543.76View SEC Filing  
10/21/2013Francesco MicheliMajor ShareholderSell124,912$62.50$7,807,000.00View SEC Filing  
10/21/2013Jonathan SilversteinDirectorSell40,088$62.50$2,505,500.00View SEC Filing  
10/21/2013Luciano AdoriniInsiderSell2,000$55.51$111,020.00View SEC Filing  
10/15/2013Francesco MicheliMajor ShareholderSell1,123,415$62.50$70,213,437.50View SEC Filing  
10/15/2013Orbimed Advisors LlcDirectorSell376,585$62.50$23,536,562.50View SEC Filing  
10/2/2013David ShapiroCMOSell4,392$72.80$319,737.60View SEC Filing  
9/20/2013Luciano AdoriniInsiderSell2,000$61.07$122,140.00View SEC Filing  
9/17/2013Mark PruzanskiCEOSell25,000$52.00$1,300,000.00View SEC Filing  
9/13/2013Mark PruzanskiCEOSell12,500$49.02$612,750.00View SEC Filing  
8/20/2013Luciano AdoriniInsiderSell2,000$44.18$88,360.00View SEC Filing  
8/16/2013David ShapiroCMOSell5,016$49.20$246,787.20View SEC Filing  
8/15/2013David ShapiroCMOSell4,754$45.04$214,120.16View SEC Filing  
8/12/2013Mark PruzanskiCEOSell12,500$45.98$574,750.00View SEC Filing  
8/12/2013Paolo FundaroDirectorSell4,759$46.13$219,532.67View SEC Filing  
7/22/2013Luciano AdoriniInsiderSell2,000$49.44$98,880.00View SEC Filing  
7/15/2013Mark PruzanskiCEOSell25,000$50.05$1,251,250.00View SEC Filing  
7/9/2013Mark PruzanskiCEOSell37,500$46.36$1,738,500.00View SEC Filing  
7/8/2013Barbara Gayle DuncanCFOSell25,000$45.39$1,134,750.00View SEC Filing  
7/2/2013David ShapiroCMOSell4,369$43.63$190,619.47View SEC Filing  
6/26/2013Mark PruzanskiCEOSell12,500$40.06$500,750.00View SEC Filing  
6/20/2013Luciano AdoriniInsiderSell2,000$37.07$74,140.00View SEC Filing  
6/20/2013Mark PruzanskiCEOSell25,000$38.25$956,250.00View SEC Filing  
6/19/2013Barbara Gayle DuncanCFOSell50,575$34.50$1,744,837.50View SEC Filing  
6/17/2013David ShapiroCMOSell5,016$32.72$164,123.52View SEC Filing  
5/28/2013Barbara Gayle DuncanCFOSell6,225$34.50$214,762.50View SEC Filing  
5/20/2013Barbara Gayle DuncanCFOSell28,200$34.50$972,900.00View SEC Filing  
5/16/2013David ShapiroCMOSell5,016$31.31$157,050.96View SEC Filing  
4/9/2013David ShapiroCMOSell3,750$34.41$129,037.50View SEC Filing  
10/16/2012Jonathan SilversteinDirectorBuy333,334$15.00$5,000,010.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Intercept Pharmaceuticals (NASDAQ:ICPT)
Latest Headlines for Intercept Pharmaceuticals (NASDAQ:ICPT)
Source:
DateHeadline
americanbankingnews.com logoIntercept Pharmaceuticals, Inc. (ICPT) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - August 18 at 8:38 AM
finance.yahoo.com logoIntercept Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ICPT) : August 15, 2017
finance.yahoo.com - August 16 at 12:03 AM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.
finance.yahoo.com - August 14 at 10:07 PM
finance.yahoo.com logoHere's My Top Stock to Buy in August
finance.yahoo.com - August 14 at 10:07 PM
nasdaq.com logoIntercept Pharmaceuticals Becomes Oversold (ICPT) - Nasdaq
www.nasdaq.com - August 9 at 7:59 PM
finance.yahoo.com logoCorporate News Blog - FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of IgA Nephropathy
finance.yahoo.com - August 8 at 7:28 PM
americanbankingnews.com logoCantor Fitzgerald Reiterates "Underweight" Rating for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
www.americanbankingnews.com - August 8 at 6:26 PM
americanbankingnews.com logoIntercept Pharmaceuticals Inc (ICPT) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - August 4 at 11:52 PM
americanbankingnews.com logoFY2017 EPS Estimates for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Lifted by Cantor Fitzgerald
www.americanbankingnews.com - August 3 at 9:52 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Intercept Pharmaceuticals, Inc. (ICPT) Raised by Analyst
www.americanbankingnews.com - August 3 at 8:28 AM
americanbankingnews.com logoIntercept Pharmaceuticals, Inc. Forecasted to Earn Q3 2017 Earnings of ($3.78) Per Share (NASDAQ:ICPT)
www.americanbankingnews.com - August 3 at 8:28 AM
americanbankingnews.com logo Analysts Anticipate Intercept Pharmaceuticals, Inc. (ICPT) Will Announce Quarterly Sales of $33.91 Million
www.americanbankingnews.com - August 3 at 7:28 AM
americanbankingnews.com logoIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Insider Rachel Mcminn Sells 130 Shares
www.americanbankingnews.com - August 2 at 10:30 PM
americanbankingnews.com logoInsider Selling: Intercept Pharmaceuticals, Inc. (ICPT) Insider Sells 142 Shares of Stock
www.americanbankingnews.com - August 2 at 10:28 PM
americanbankingnews.com logoInsider Selling: Intercept Pharmaceuticals, Inc. (ICPT) Director Sells 602 Shares of Stock
www.americanbankingnews.com - August 2 at 10:28 PM
americanbankingnews.com logoDavid Shapiro Sells 1,118 Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Stock
www.americanbankingnews.com - August 2 at 10:28 PM
americanbankingnews.com logoFY2020 EPS Estimates for Intercept Pharmaceuticals, Inc. Lifted by Wedbush (ICPT)
www.americanbankingnews.com - August 2 at 5:24 PM
americanbankingnews.com logoIntercept Pharmaceuticals, Inc. to Post Q3 2017 Earnings of ($3.55) Per Share, Jefferies Group Forecasts (ICPT)
www.americanbankingnews.com - August 2 at 7:02 AM
americanbankingnews.com logoIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to Post Q3 2017 Earnings of ($3.49) Per Share, Oppenheimer Holdings Forecasts
www.americanbankingnews.com - August 2 at 7:02 AM
americanbankingnews.com logoIntercept Pharmaceuticals, Inc. (ICPT) Price Target Increased to $221.00 by Analysts at BMO Capital Markets
www.americanbankingnews.com - August 1 at 6:34 PM
americanbankingnews.com logoOppenheimer Holdings, Inc. Reaffirms Outperform Rating for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
www.americanbankingnews.com - August 1 at 3:56 PM
americanbankingnews.com logoBrokers Offer Predictions for Intercept Pharmaceuticals, Inc.'s FY2020 Earnings (NASDAQ:ICPT)
www.americanbankingnews.com - August 1 at 3:52 PM
finance.yahoo.com logoIntercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US : August 1, 2017
finance.yahoo.com - August 1 at 3:20 PM
finance.yahoo.com logoIntercept (ICPT) Posts Narrower-than-Expected Loss in Q2
finance.yahoo.com - August 1 at 3:20 PM
finance.yahoo.com logoEdited Transcript of ICPT earnings conference call or presentation 31-Jul-17 12:30pm GMT
finance.yahoo.com - August 1 at 12:10 AM
streetinsider.com logoIntercept Pharma (ICPT) Says Phase 2 AESOP Trial Evaluating OCA for Treatment of Patients with Primary Sclerosing Cholangitis Met Primary Endpoint
www.streetinsider.com - July 31 at 7:08 PM
seekingalpha.com logoIntercept Pharmaceuticals (ICPT) Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - July 31 at 7:08 PM
finance.yahoo.com logoIntercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - July 31 at 7:08 PM
finance.yahoo.com logoIntercept Announces Positive Results from the Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis
finance.yahoo.com - July 31 at 7:08 PM
finance.yahoo.com logoIntercept (ICPT) Reports a Narrower Q2 Loss
finance.yahoo.com - July 31 at 7:08 PM
finance.yahoo.com logoInvestor Network: Intercept Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - July 31 at 7:08 PM
finance.yahoo.com logoIntercept Pharma shares drop 2% despite Q2 profit, revenue beats and positive clinical trial results
finance.yahoo.com - July 31 at 7:08 PM
finance.yahoo.com logoIntercept reports 2Q loss
finance.yahoo.com - July 31 at 7:08 PM
americanbankingnews.com logoIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Receives "Buy" Rating from Wedbush
www.americanbankingnews.com - July 31 at 4:28 PM
americanbankingnews.com logoIntercept Pharmaceuticals, Inc. (ICPT) Receives "Underweight" Rating from Cantor Fitzgerald
www.americanbankingnews.com - July 31 at 4:28 PM
americanbankingnews.com logoIntercept Pharmaceuticals, Inc. (ICPT) Releases Earnings Results, Beats Expectations By $0.15 EPS
www.americanbankingnews.com - July 31 at 9:26 AM
feeds.benzinga.com logoCONTROL Trial Shows Statin Therapy Reversed LDL Increases to Below Baseline Levels in NASH Patients Treated with OCA
feeds.benzinga.com - July 31 at 7:34 AM
americanbankingnews.com logoIntercept Pharmaceuticals, Inc. (ICPT) Receives "Buy" Rating from Jefferies Group LLC
www.americanbankingnews.com - July 30 at 10:26 PM
finance.yahoo.com logo3 Growth Stocks That Could Soar More Than Dollar Tree
finance.yahoo.com - July 26 at 4:12 PM
feeds.benzinga.com logoIntercept to Report Second Quarter 2017 Financial Results on July 31
feeds.benzinga.com - July 26 at 7:49 AM
finance.yahoo.com logoCan Intercept (ICPT) Beat Estimates this Earnings Season?
finance.yahoo.com - July 25 at 8:01 PM
americanbankingnews.com logoIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - July 24 at 10:16 AM
americanbankingnews.com logoDaniel G. Welch Sells 217 Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Stock
www.americanbankingnews.com - July 22 at 7:22 AM
finance.yahoo.com logoThe Best Stock in New York: Intercept Pharmaceuticals
finance.yahoo.com - July 21 at 4:15 PM
americanbankingnews.com logoIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) SVP Richard J. Kim Sells 89 Shares
www.americanbankingnews.com - July 18 at 10:28 PM
americanbankingnews.com logoBidaskClub Upgrades Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to "Buy"
www.americanbankingnews.com - July 16 at 2:06 PM
americanbankingnews.com logoIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) CMO Sells $68,577.53 in Stock
www.americanbankingnews.com - July 13 at 10:52 PM
americanbankingnews.com logoBrokers Offer Predictions for Intercept Pharmaceuticals, Inc.'s Q2 2017 Earnings (NASDAQ:ICPT)
www.americanbankingnews.com - July 13 at 8:29 AM
americanbankingnews.com logoZacks: Analysts Expect Intercept Pharmaceuticals, Inc. (ICPT) Will Announce Quarterly Sales of $26.70 Million
www.americanbankingnews.com - July 12 at 9:51 AM
americanbankingnews.com logoIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - July 11 at 4:52 PM

Social

Chart

Intercept Pharmaceuticals (ICPT) Chart for Sunday, August, 20, 2017

This page was last updated on 8/20/2017 by MarketBeat.com Staff